SK285371B6 - Aryl- a heteroaryl-substituované heterocyklické močoviny, ich použitie a farmaceutické kompozície sich obsahom - Google Patents
Aryl- a heteroaryl-substituované heterocyklické močoviny, ich použitie a farmaceutické kompozície sich obsahom Download PDFInfo
- Publication number
- SK285371B6 SK285371B6 SK962-2000A SK9622000A SK285371B6 SK 285371 B6 SK285371 B6 SK 285371B6 SK 9622000 A SK9622000 A SK 9622000A SK 285371 B6 SK285371 B6 SK 285371B6
- Authority
- SK
- Slovakia
- Prior art keywords
- substituted
- group
- alkyl
- halogen
- phenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99618197A | 1997-12-22 | 1997-12-22 | |
| PCT/US1998/026082 WO1999032455A1 (en) | 1997-12-22 | 1998-12-22 | Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK9622000A3 SK9622000A3 (en) | 2001-01-18 |
| SK285371B6 true SK285371B6 (sk) | 2006-12-07 |
Family
ID=25542594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK962-2000A SK285371B6 (sk) | 1997-12-22 | 1998-12-22 | Aryl- a heteroaryl-substituované heterocyklické močoviny, ich použitie a farmaceutické kompozície sich obsahom |
Country Status (29)
| Country | Link |
|---|---|
| EP (1) | EP1056725B1 (no) |
| JP (1) | JP4395823B2 (no) |
| KR (1) | KR100622138B1 (no) |
| CN (1) | CN1117081C (no) |
| AT (1) | ATE328873T1 (no) |
| AU (1) | AU765412B2 (no) |
| BG (1) | BG65207B1 (no) |
| BR (1) | BR9814361A (no) |
| CA (1) | CA2315713C (no) |
| CU (1) | CU23127A3 (no) |
| CY (1) | CY1105395T1 (no) |
| CZ (1) | CZ299836B6 (no) |
| DE (2) | DE1056725T1 (no) |
| DK (1) | DK1056725T3 (no) |
| ES (1) | ES2155045T3 (no) |
| GR (1) | GR20010300010T1 (no) |
| HK (1) | HK1029989A1 (no) |
| HU (1) | HUP0004426A3 (no) |
| ID (1) | ID26328A (no) |
| IL (2) | IL136773A0 (no) |
| NO (1) | NO319209B1 (no) |
| NZ (1) | NZ505845A (no) |
| PL (1) | PL341356A1 (no) |
| PT (1) | PT1056725E (no) |
| RU (1) | RU2265597C2 (no) |
| SK (1) | SK285371B6 (no) |
| TR (3) | TR200100918T2 (no) |
| UA (1) | UA67763C2 (no) |
| WO (1) | WO1999032455A1 (no) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1473292A1 (en) * | 1997-11-03 | 2004-11-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
| MXPA00006233A (es) * | 1997-12-22 | 2002-09-18 | Bayer Ag | Inhibicion de la actividad de la cinasa p38 utilizando ureas heterociclicas sustituidas. |
| IL136768A0 (en) * | 1997-12-22 | 2001-06-14 | Bayer Ag | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS |
| KR100571588B1 (ko) * | 1997-12-22 | 2006-04-17 | 바이엘 코포레이션 | 치환 헤테로시클릭 우레아를 이용한 ｒａｆ 키나제의 억제 |
| AU2006201959B2 (en) * | 1997-12-22 | 2008-09-04 | Bayer Healthcare Llc | Inhibition of Raf Kinase using Substituted Heterocyclic Ureas |
| EP2298311B1 (en) | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7928239B2 (en) * | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| EP1157026A1 (en) | 1999-02-22 | 2001-11-28 | Boehringer Ingelheim Pharmaceuticals Inc. | Polycyclo heterocyclic derivatives as antiinflammatory agents |
| WO2000051998A1 (en) | 1999-03-02 | 2000-09-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cathepsin s |
| CA2361998C (en) | 1999-03-12 | 2009-04-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
| ID30176A (id) | 1999-03-12 | 2001-11-08 | Boehringer Ingelheim Pharma | Senyawa-senyawa yang bermanfaat sebagai zat anti-inflamasi |
| EP1200411B1 (en) | 1999-07-09 | 2005-12-14 | Boehringer Ingelheim Pharmaceuticals Inc. | Process for synthesis of heteroaryl-substituted urea compounds |
| EA005373B1 (ru) | 1999-08-12 | 2005-02-24 | Фармация Италия С.П.А. | Производные 3(5)-аминопиразола, способ их получения и их применение в качестве противоопухолевых средств |
| US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
| EP1232153B1 (en) * | 1999-11-22 | 2004-11-03 | SmithKline Beecham plc | Imidazole derivatives and their use as raf kinase inhibitors |
| US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
| US6608052B2 (en) | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
| ZA200301813B (en) * | 2000-08-10 | 2004-06-22 | Pharmacia Italia Spa | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them. |
| US6645990B2 (en) | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
| US7238813B2 (en) | 2000-11-29 | 2007-07-03 | Smithkline Beecham Corporation | Chemical compounds |
| EP1392661A1 (en) | 2001-05-16 | 2004-03-03 | Boehringer Ingelheim Pharmaceuticals Inc. | Diarylurea derivatives useful as anti-inflammatory agents |
| MXPA03010724A (es) | 2001-05-25 | 2004-03-02 | Boehringer Ingelheim Pharma | Compuestos de carbamato y oxamida como inhibidores de la produccion de citocina. |
| EP1709965A3 (en) * | 2001-07-11 | 2006-12-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating cytokine mediate diseases |
| EP1423383B1 (en) | 2001-09-05 | 2008-08-06 | Smithkline Beecham Plc | Pyridine substituted furan derivatives as raf kinase inhibitors |
| ES2400070T3 (es) * | 2001-12-03 | 2013-04-05 | Bayer Healthcare Llc | Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos |
| US10653684B2 (en) | 2002-02-11 | 2020-05-19 | Bayer Healthcare Llc | Aryl ureas with angiogenisis inhibiting activity |
| WO2003068223A1 (en) * | 2002-02-11 | 2003-08-21 | Bayer Corporation | Aryl ureas with raf kinase and angiogenesis inhibiting activity |
| EP1474393A1 (en) | 2002-02-11 | 2004-11-10 | Bayer Pharmaceuticals Corporation | Aryl ureas as kinase inhibitors |
| SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
| US7041669B2 (en) | 2002-02-25 | 2006-05-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-benzofused urea compounds useful in treating cytokine mediated diseases |
| MXPA05000945A (es) * | 2002-07-25 | 2005-05-16 | Pharmacia Italia Spa | Biciclo-pirazoles activos como inhibidores de la cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| CA2516931C (en) | 2003-02-28 | 2014-09-09 | Bayer Pharmaceuticals Corporation | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| JP4939220B2 (ja) | 2003-05-15 | 2012-05-23 | アークル インコーポレイテッド | ｐ３８の阻害物質としてのイミダゾチアゾール類およびイミダゾオキサゾール誘導体 |
| JP2007511203A (ja) | 2003-05-20 | 2007-05-10 | バイエル、ファーマシューテイカルズ、コーポレイション | キナーゼ阻害活性を有するジアリール尿素 |
| SI1663978T1 (sl) | 2003-07-23 | 2008-02-29 | Bayer Pharmaceuticals Corp | Fluoro substituirana omega-karboksiaril difenil secnina za zdravljenje ali preprecevanje bolezni instanj |
| EP1684762A4 (en) | 2003-11-13 | 2009-06-17 | Ambit Biosciences Corp | UREA DERIVATIVES AS MODULATORS OF KINASE |
| TW200530236A (en) | 2004-02-23 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Heteroaryl phenylurea |
| US20060211752A1 (en) | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| WO2005092871A2 (en) * | 2004-03-19 | 2005-10-06 | Dipharma S.P.A. | Intermediates for the preparation of pramipexole |
| WO2005110994A2 (en) | 2004-04-30 | 2005-11-24 | Bayer Pharmaceuticals Corporation | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
| US7829560B2 (en) | 2004-07-08 | 2010-11-09 | Arqule, Inc. | 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase |
| MY191349A (en) * | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
| WO2006044869A1 (en) | 2004-10-19 | 2006-04-27 | Arqule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
| GB0423554D0 (en) * | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| CA2592118C (en) | 2004-12-23 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Urea derivatives as enzyme modulators |
| GB0500435D0 (en) * | 2005-01-10 | 2005-02-16 | Novartis Ag | Organic compounds |
| DK1868579T3 (da) | 2005-03-07 | 2011-01-10 | Bayer Schering Pharma Ag | Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer |
| JP5072595B2 (ja) | 2005-08-05 | 2012-11-14 | 中外製薬株式会社 | マルチキナーゼ阻害剤 |
| DE102005037499A1 (de) * | 2005-08-09 | 2007-02-15 | Merck Patent Gmbh | Pyrazolderivate |
| EP1960394A2 (en) * | 2005-11-15 | 2008-08-27 | Bayer HealthCare AG | Pyrazolyl urea derivatives useful in the treatment of cancer |
| CA2634084C (en) * | 2005-12-21 | 2015-04-07 | Roger Smith | Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders |
| EP2338488A1 (en) | 2006-05-26 | 2011-06-29 | Bayer HealthCare, LLC | Drug combinations with substituted diaryl ureas for the treatment of cancer |
| US7897762B2 (en) | 2006-09-14 | 2011-03-01 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of proliferative diseases |
| JP2010514692A (ja) | 2006-12-20 | 2010-05-06 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌の治療に有用なヒドロキシメチルフェニルピラゾリル尿素化合物 |
| US7737149B2 (en) * | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| CA2682162C (en) | 2007-04-02 | 2016-05-10 | Renovis, Inc. | Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof |
| EP2146716A4 (en) | 2007-04-20 | 2010-08-11 | Deciphera Pharmaceuticals Llc | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYELOPROLIFERATIVE SYNDROME AND OTHER PROLIFERATIVE DISEASES |
| TW200940540A (en) | 2008-02-29 | 2009-10-01 | Array Biopharma Inc | RAF inhibitor compounds and methods of use thereof |
| MX2010009411A (es) | 2008-02-29 | 2010-11-30 | Array Biopharma Inc | Compuestos del inhibidor de raf y métodos de uso de los mismos. |
| GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
| MY159230A (en) | 2008-10-02 | 2016-12-30 | Respivert Ltd | P38 map kinase inhibitors |
| CA2746354A1 (en) | 2008-12-11 | 2010-06-17 | Respivert Limited | P38 map kinase inhibitors |
| GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| WO2011124923A2 (en) | 2010-04-08 | 2011-10-13 | Respivert Limited | Novel compounds |
| WO2012008563A1 (ja) | 2010-07-16 | 2012-01-19 | 協和発酵キリン株式会社 | 含窒素芳香族複素環誘導体 |
| JP2013531067A (ja) | 2010-07-19 | 2013-08-01 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬 |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| PL2763984T3 (pl) | 2011-10-03 | 2016-10-31 | 1-pirazolilo-3-(4-((2-anilinopirymidyno-4-ilo)oksy)naftaleno-1-ilo)moczniki jako inhibitory kinazy p38 MAP | |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| KR20140011780A (ko) * | 2012-07-19 | 2014-01-29 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체 |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| EP2970190A1 (en) | 2013-03-14 | 2016-01-20 | Respivert Limited | Kinase inhibitors |
| US9750723B2 (en) | 2013-10-31 | 2017-09-05 | Ohio University | Prevention and treatment of non-alcoholic fatty liver disease |
| TR201809072T4 (tr) | 2014-02-14 | 2018-07-23 | Respivert Ltd | Antiinflamatuvar bileşikler olarak aromatik heterosiklik bileşikler. |
| US10392381B2 (en) | 2014-07-18 | 2019-08-27 | Ohio University | Prevention and treatment of non-alcoholic fatty liver disease |
| SG11202007287XA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of mastocytosis |
| KR20240140193A (ko) | 2018-01-31 | 2024-09-24 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양의 치료를 위한 병용 요법 |
| LT3762368T (lt) | 2018-03-08 | 2022-06-10 | Incyte Corporation | Aminopirazindiolio junginiai, kaip pi3k-γ inhibitoriai |
| CN108484587A (zh) * | 2018-06-03 | 2018-09-04 | 刘思良 | 一种Raf激酶抑制剂及其在癌症治疗中的应用 |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| EP3818044A1 (en) * | 2018-07-03 | 2021-05-12 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| CA3150433A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
| TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| AU2020419197B2 (en) | 2019-12-30 | 2023-08-31 | Deciphera Pharmaceuticals, Llc | Amorphous kinase inhibitor formulations and methods of use thereof |
| KR20220123058A (ko) | 2019-12-30 | 2022-09-05 | 데시페라 파마슈티칼스, 엘엘씨. | 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물 |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5162360A (en) * | 1991-06-24 | 1992-11-10 | Warner-Lambert Company | 2-heteroatom containing urea and thiourea ACAT inhibitors |
| GB9302275D0 (en) * | 1993-02-05 | 1993-03-24 | Smithkline Beecham Plc | Novel compounds |
| US5773459A (en) * | 1995-06-07 | 1998-06-30 | Sugen, Inc. | Urea- and thiourea-type compounds |
| GB9623833D0 (en) * | 1996-11-16 | 1997-01-08 | Zeneca Ltd | Chemical compound |
| JP2002500650A (ja) * | 1997-05-23 | 2002-01-08 | バイエル、コーポレイション | Ｒａｆキナーゼ阻害剤 |
| CA2308428A1 (en) * | 1997-11-03 | 1999-05-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
| IL136768A0 (en) * | 1997-12-22 | 2001-06-14 | Bayer Ag | INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS |
-
1998
- 1998-12-22 KR KR1020007007014A patent/KR100622138B1/ko not_active IP Right Cessation
- 1998-12-22 ID IDW20001417A patent/ID26328A/id unknown
- 1998-12-22 PT PT98963810T patent/PT1056725E/pt unknown
- 1998-12-22 CA CA2315713A patent/CA2315713C/en not_active Expired - Fee Related
- 1998-12-22 DK DK98963810T patent/DK1056725T3/da active
- 1998-12-22 CZ CZ20002349A patent/CZ299836B6/cs not_active IP Right Cessation
- 1998-12-22 TR TR2001/00918T patent/TR200100918T2/xx unknown
- 1998-12-22 JP JP2000525392A patent/JP4395823B2/ja not_active Expired - Fee Related
- 1998-12-22 RU RU2000120162/04A patent/RU2265597C2/ru not_active IP Right Cessation
- 1998-12-22 AU AU19055/99A patent/AU765412B2/en not_active Ceased
- 1998-12-22 TR TR2001/00917T patent/TR200100917T2/xx unknown
- 1998-12-22 TR TR2000/02617T patent/TR200002617T2/xx unknown
- 1998-12-22 BR BR9814361-1A patent/BR9814361A/pt not_active IP Right Cessation
- 1998-12-22 CN CN98812504A patent/CN1117081C/zh not_active Expired - Fee Related
- 1998-12-22 UA UA2000074353A patent/UA67763C2/uk unknown
- 1998-12-22 IL IL13677398A patent/IL136773A0/xx active IP Right Grant
- 1998-12-22 EP EP98963810A patent/EP1056725B1/en not_active Expired - Lifetime
- 1998-12-22 NZ NZ505845A patent/NZ505845A/en not_active IP Right Cessation
- 1998-12-22 PL PL98341356A patent/PL341356A1/xx not_active Application Discontinuation
- 1998-12-22 ES ES98963810T patent/ES2155045T3/es not_active Expired - Lifetime
- 1998-12-22 DE DE1056725T patent/DE1056725T1/de active Pending
- 1998-12-22 SK SK962-2000A patent/SK285371B6/sk not_active IP Right Cessation
- 1998-12-22 DE DE69834842T patent/DE69834842T2/de not_active Expired - Lifetime
- 1998-12-22 HU HU0004426A patent/HUP0004426A3/hu unknown
- 1998-12-22 WO PCT/US1998/026082 patent/WO1999032455A1/en active IP Right Grant
- 1998-12-22 AT AT98963810T patent/ATE328873T1/de active
-
2000
- 2000-06-14 IL IL136773A patent/IL136773A/en not_active IP Right Cessation
- 2000-06-21 NO NO20003231A patent/NO319209B1/no not_active IP Right Cessation
- 2000-06-22 CU CU152A patent/CU23127A3/es not_active IP Right Cessation
- 2000-07-12 BG BG104598A patent/BG65207B1/bg unknown
-
2001
- 2001-01-30 HK HK01100659A patent/HK1029989A1/xx not_active IP Right Cessation
- 2001-03-30 GR GR20010300010T patent/GR20010300010T1/el unknown
-
2006
- 2006-09-06 CY CY20061101275T patent/CY1105395T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK285371B6 (sk) | Aryl- a heteroaryl-substituované heterocyklické močoviny, ich použitie a farmaceutické kompozície sich obsahom | |
| US7329670B1 (en) | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas | |
| EP1379505B1 (en) | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas | |
| EP1047418B1 (en) | Inhibition of raf kinase using substituted heterocyclic ureas | |
| US20120129893A1 (en) | Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas | |
| BG64594B1 (bg) | Инхибиране на raf - киназа чрез използване на симетрично и несиметрично заместени дифенилкарбамиди | |
| US7371763B2 (en) | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas | |
| US20030207914A1 (en) | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas | |
| MXPA00006228A (en) | Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas | |
| MXPA00006226A (en) | Inhibition of raf kinase using substituted heterocyclic ureas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC4A | Assignment and transfer of rights |
Owner name: BAYER HEALTHCARE LLC, TARRYTOWN, NEW YORK, US Free format text: FORMER OWNER: BAYER CORPORATION, PITTSBURGH, PA, US Effective date: 20110107 |
|
| MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20131222 |